Jane Street Group, LLC Akebia Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 123,728 shares of AKBA stock, worth $221,473. This represents 0.0% of its overall portfolio holdings.

Number of Shares

123,728

Previous 126,494 2.19%

Holding current value

$221,473

Previous $129,000 26.36%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.94 - $1.55 $2,600 - $4,287	-2,766 Reduced 2.19%	123,728 $163,000
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $233,546 - $442,652	-271,566 Reduced 68.22%	126,494 $129,000
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $381,656 - $673,158	300,517 Added 308.09%	398,060 $728,000
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $29,897 - $47,836	37,372 Added 62.11%	97,543 $120,000
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $2,662 - $5,630	3,060 Added 5.36%	60,171 $68,000
Q2 2023 Aug 14, 2023	BUY	$0.51 - $1.43 $5,568 - $15,612	10,918 Added 23.64%	57,111 $52,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $267,405 - $549,136	-477,510 Reduced 91.18%	46,193 $25,000
Q4 2022 Feb 14, 2023	BUY	$0.25 - $0.58 $128,266 - $297,577	513,064 Added 4822.48%	523,703 $303,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $45,458 - $69,702	-151,527 Reduced 93.44%	10,639 $3,000
Q2 2022 Aug 16, 2022	SELL	$0.32 - $0.67 $124,313 - $260,282	-388,481 Reduced 70.55%	162,166 $57,000
Q1 2022 May 17, 2022	BUY	$0.72 - $2.93 $190,040 - $773,358	263,945 Added 92.06%	550,647 $395,000
Q4 2021 Feb 15, 2022	BUY	$2.26 - $3.34 $275,803 - $407,603	122,037 Added 74.11%	286,702 $648,000
Q3 2021 Nov 16, 2021	BUY	$2.35 - $3.88 $207,660 - $342,860	88,366 Added 115.82%	164,665 $474,000
Q2 2021 Aug 16, 2021	BUY	$2.83 - $4.2 $123,784 - $183,708	43,740 Added 134.34%	76,299 $289,000
Q1 2021 May 18, 2021	SELL	$2.92 - $5.06 $128,722 - $223,059	-44,083 Reduced 57.52%	32,559 $110,000
Q4 2020 Feb 17, 2021	SELL	$2.22 - $3.78 $75,211 - $128,062	-33,879 Reduced 30.65%	76,642 $215,000
Q3 2020 Nov 17, 2020	BUY	$2.39 - $13.08 $175,923 - $962,792	73,608 Added 199.41%	110,521 $277,000
Q2 2020 Aug 17, 2020	BUY	$6.67 - $13.58 $142,671 - $290,476	21,390 Added 137.8%	36,913 $501,000
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $17,548 - $43,827	4,280 Added 38.07%	15,523 $118,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $66,211 - $141,013	-20,953 Reduced 65.08%	11,243 $71,000
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $301,718 - $458,951	-84,991 Reduced 72.53%	32,196 $126,000
Q2 2019 Aug 15, 2019	BUY	$4.1 - $8.05 $480,466 - $943,355	117,187 New	117,187 $567,000
Q1 2019 May 16, 2019	SELL	$5.41 - $8.73 $55,549 - $89,639	-10,268 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$5.39 - $9.15 $55,344 - $93,952	10,268 New	10,268 $57,000
Q2 2018 Aug 15, 2018	SELL	$9.15 - $11.34 $91,719 - $113,672	-10,024 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $95,528 - $157,176	10,024 New	10,024 $96,000

Others Institutions Holding AKBA

# of Institutions

121

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Akebia Therapeutics, Inc. Transaction History